PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy

Daniele Musiani, Dean E. Hammond, Luca Cirillo, Jessica Erriquez, Martina Olivero, Michael J. Clague, Maria Flavia Di Renzo

Research output: Contribution to journalArticlepeer-review


Platinum-based chemotherapy is widely used to treat various cancers, but many patients ultimately relapse due to drug resistance. We employed phosphoproteomic analysis and functional assays of the response of SK-OV-3 ovarian cancer cells to cisplatin as a strategy to identify kinases as candidate druggable targets to sensitize cells to platinum. A SILAC-based approach combined with TiO2-based phosphopeptide enrichment allowed the direct identification of ERK1/2, p90RSK, and ERBB2 as kinases whose phosphorylation is regulated by cisplatin. Bioinformatic analysis revealed enrichment in linear phosphorylation motifs predicted to be targets of p38MAPK, CDK2, and PIM2. All three PIM kinases were found expressed in a panel of 10 ovarian cancer cell lines, with the oncogenic PIM2 being the most commonly induced by cisplatin. Targeting PIM2 kinase by either biochemical inhibitors or RNA interference impaired cell growth, decreased cisplatin-triggered BAD phosphorylation, and sensitized ovarian cancer cells to drug-induced apoptosis. Overexpression of PIM2 triggered anchorage-independent growth and resulted in increased BAD phosphorylation and cell resistance to DNA damaging agents. The data show that the PIM2 kinase plays a role in the response of ovarian cancer cells to platinum drugs and suggest that PIM inhibitors may find clinical application as an adjunct to platinum-based therapies.

Original languageEnglish
Pages (from-to)4970-4982
Number of pages13
JournalJournal of Proteome Research
Issue number11
Publication statusPublished - Nov 7 2014


  • ovarian cancer
  • PIM2 kinase
  • platinum drugs
  • SILAC phosphoproteomics

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)
  • Medicine(all)

Fingerprint Dive into the research topics of 'PIM2 kinase is induced by cisplatin in ovarian cancer cells and limits drug efficacy'. Together they form a unique fingerprint.

Cite this